

SUSPECT ADVERSE REACTION REPORT										
Page 1										
I. Reaction Information										
1. Patient's Initials		2a. Country		3. Date of Birth			2b. Age		3. Sex	
				Day Mo Yr			Yes		4. Hispanic Origin	
									Day Mo Yr	
7. Describe reaction(s) (including relevant laboratory data)										
<p>CHECK ALL APPROPRIATE TO REACTION</p> <input type="checkbox"/> Patient died <input type="checkbox"/> Involved or processed against medical recommendation <input type="checkbox"/> Involved against disability or incapacity <input type="checkbox"/> Life threatening										
II. Suspect Drug Information										
14. Suspect (Drugs) (include generic name)										
15. Daily dose(s)					16. Route(s) of administration					
17. Indication(s) for use										
18. Therapy dates (month)					19. Therapy duration					
20. Did reaction abate after stopping drug? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> N/A										
21. Did reaction reappear after reintroduction? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> N/A										
III. Concomitant Drugs and History										
22. Concomitant drugs and dates of administration (include those used to treat reaction)										
23. Other relevant history (eg, diagnosis, allergies, pregnancy with MVD, etc.)										
<div style="border: 1px solid black; padding: 5px; width: fit-content; margin: auto;"> Submission of this report does not necessarily constitute a claim or admission that the drug caused the adverse effect. </div>										
IV. Manufacturer Information					V. Initial Reporter (In confidence)					
24a. Name and address of manufacturer					25-25a. Name and address of reporter (include zip code)					
24c. Date received by manufacturer					26. Mfr. Control No.					
Date of this report					26a. Report Source					
					<input type="checkbox"/> Study <input type="checkbox"/> Literature					
					<input type="checkbox"/> Health Professional					
					<input type="checkbox"/> Initial <input type="checkbox"/> Follow-up					
CONFIDENTIAL										

TN 97-22 (06/11/97), Compliance Program 7353.001